Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma

Author:

Zhu Andrew X.1,Baron Ari David2,Malfertheiner Peter3,Kudo Masatoshi4,Kawazoe Seiji5,Pezet Denis6,Weissinger Florian7,Brandi Giovanni8,Barone Carlo A.9,Okusaka Takuji10,Wada Yoshiyuki11,Park Joon Oh12,Ryoo Baek-Yeol13,Cho Jae Yong14,Chung Hyun Cheol15,Li Chung-Pin16,Yen Chia-Jui17,Lee Kuan-Der18,Chang Shao-Chun19,Yang Ling20,Abada Paolo B.21,Chau Ian22

Affiliation:

1. Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston

2. California Pacific Medical Center, San Francisco

3. Otto von Guericke University of Magdeburg, Magdeburg, Germany

4. Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japan

5. Saga-Ken Medical Centre Koseikan, Saga, Japan

6. Surgery Department CHU Estaing, Clermond Ferrand, France

7. Evangelisches Krankenhaus Bielefeld, Bielefeld, Germany

8. Policlinico Sant' Orsola-Malpighi, Bologna, Italy

9. Catholic University of Sacred Heart, Rome, Italy

10. Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan

11. National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

12. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

13. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

14. Gangnam Severance Hospital, Seoul, South Korea

15. Yonsei Cancer Center, Cancer Metastasis Research Center, Yonsei University College of Medicine, Shinchon-Dong, South Korea

16. Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan17National Yang-Ming University School of Medicine, Taipei, Taiwan

17. National Cheng Kung University Hospital, Tainan City, Taiwan

18. Chang Gung Memorial Hospital, Chiayi, Taiwan

19. Eli Lilly and Company, Bridgewater, New Jersey

20. AstraZeneca Pharmaceuticals, Wilmington, Delaware

21. Eli Lilly and Company, Indianapolis, Indiana

22. Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3